Drug intelligence / Profile preview

Zonaguard

Development stage: Preclinical
Lead developer: NIVAD Pharmed Salamat
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Zonaguard is a recombinant subunit vaccine developed by NIVAD Pharmed Salamat for the prevention of herpes zoster (shingles) and post-herpetic neuralgia (PHN) in adults. It is designed to induce a robust immune response against the varicella-zoster virus (VZV), preventing the reactivation of the latent virus that causes shingles and its associated long-term neuropathic pain complications. As a recombinant subunit vaccine, it represents a non-live alternative to traditional live-attenuated vaccines, offering a safer profile particularly for older adults and immunocompromised populations.

Brand names: Zonaguard
Other names: زوناگارد

Targets

gE (VZV glycoprotein E)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on Zonaguard.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zonaguard.

Explore the full profile